Chemical Genomics Centre of the Max Planck Society, Otto-Hahn-Strasse 15, 44227 Dortmund, Germany.
Mol Cell Biol. 2010 Oct;30(19):4698-711. doi: 10.1128/MCB.01636-09. Epub 2010 Aug 2.
The Ras-RAF-mitogen-activated protein kinase (Ras-RAF-MAPK) pathway is overactive in many cancers and in some developmental disorders. In one of those disorders, namely, Noonan syndrome, nine activating C-RAF mutations cluster around Ser(259), a regulatory site for inhibition by 14-3-3 proteins. We show that these mutations impair binding of 14-3-3 proteins to C-RAF and alter its subcellular localization by promoting Ras-mediated plasma membrane recruitment of C-RAF. By presenting biophysical binding data, the 14-3-3/C-RAFpS(259) crystal structure, and cellular analyses, we indicate a mechanistic link between a well-described human developmental disorder and the impairment of a 14-3-3/target protein interaction. As a broader implication of these findings, modulating the C-RAFSer(259)/14-3-3 protein-protein interaction with a stabilizing small molecule may yield a novel potential approach for treatment of diseases resulting from an overactive Ras-RAF-MAPK pathway.
Ras-RAF-丝裂原活化蛋白激酶(Ras-RAF-MAPK)通路在许多癌症和一些发育障碍中过度活跃。在其中一种疾病,即诺南综合征中,九个激活的 C-RAF 突变聚集在 Ser(259)周围,Ser(259)是受 14-3-3 蛋白抑制的调节位点。我们表明,这些突变会损害 14-3-3 蛋白与 C-RAF 的结合,并通过促进 Ras 介导的 C-RAF 向质膜募集来改变其细胞内定位。通过提供生物物理结合数据、14-3-3/C-RAFpS(259)晶体结构和细胞分析,我们表明了一种机制联系,即将描述的人类发育障碍与 14-3-3/靶蛋白相互作用的损害联系起来。作为这些发现的更广泛意义,用稳定的小分子调节 C-RAFSer(259)/14-3-3 蛋白-蛋白相互作用可能为治疗由于 Ras-RAF-MAPK 通路过度活跃而导致的疾病提供一种新的潜在方法。